Hospira (HSP) Tops Q3 EPS by 21c; Sees FY EPS at Upper End of Prior Range

Hospira (NYSE: HSP) reported Q3 EPS of $0.74, $0.21 better than the analyst estimate of $0.53. Revenue for the quarter came in at $1.15 billion versus the consensus estimate of $1.08 billion.

Hospira sees FY2014 EPS of $2.40-$2.50, the upper-end of its prior range.

For earnings history and earnings-related data on Hospira (HSP) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'